Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, but identifying such stocks can be challenging due to inherent risks and volatility [1] Group 1: Growth Stock Identification - The Zacks Growth Style Score system aids in identifying promising growth stocks by analyzing real growth prospects beyond traditional metrics [2] - ANI Pharmaceuticals (ANIP) is currently highlighted as a recommended growth stock, possessing a favorable Growth Score and a top Zacks Rank [2] Group 2: Earnings Growth - Earnings growth is a critical factor for growth investors, with double-digit growth being particularly attractive as it signals strong future prospects [3] - ANI's projected EPS growth for the current year is 22.3%, significantly surpassing the industry average of 16% [4] Group 3: Cash Flow Growth - High cash flow growth is essential for growth-oriented companies, allowing them to fund new projects without relying on external financing [5] - ANI's year-over-year cash flow growth stands at 22.1%, in stark contrast to the industry average of -4.2% [5] - The company's historical annualized cash flow growth rate over the past 3-5 years is 10.4%, compared to the industry average of 3.6% [6] Group 4: Earnings Estimate Revisions - Positive trends in earnings estimate revisions are correlated with stock price movements, making them an important consideration for investors [7] - ANI has experienced upward revisions in current-year earnings estimates, with the Zacks Consensus Estimate increasing by 0.5% over the past month [7] Group 5: Overall Positioning - ANI has achieved a Growth Score of B and a Zacks Rank 1 due to positive earnings estimate revisions, positioning it well for potential outperformance [9]

The U.S. stock market will likely remain volatile as the trade war with China is yet to be resolved. Based on political negotiations and public statements, the market will continue to be subject to rapid changes. Hence, uncertainty prevails in the market as investors don’t have any visibility about the near-term economic and policy outlook.In this context, creating a curated portfolio of low-beta stocks is a prudent strategy. This provides a safeguard against the uncertain market, equipping investors to nav ...

U.S. stock markets are witnessing extreme volatility in April due to the Trump administration’s tariffs on imported products from around the world. The baseline tariff of 10% was imposed on all imports on April 5.This seems to be the beginning of a global trade war. Economists and financial experts are highly concerned about the impact of these tariffs on U.S. economic growth, especially on inflation, which is already elevated and prolonged. Market participants fear a near-term recession and, in the worst-c ...

Have you been paying attention to shares of ANI Pharmaceuticals (ANIP) ? Shares have been on the move with the stock up 6.7% over the past month. The stock hit a new 52-week high of $70.18 in the previous session. ANI Pharmaceuticals has gained 25.2% since the start of the year compared to the -5.4% move for the Zacks Medical sector and the -8.4% return for the Zacks Medical - Biomedical and Genetics industry.What's Driving the Outperformance?The stock has a great record of positive earnings surprises, as i ...

Growth investors focus on stocks that are seeing above-average financial growth, as this feature helps these securities garner the market's attention and deliver solid returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks ...

PRINCETON, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (NASDAQ:ANIP) today announced that the Company will release its first quarter 2025 financial results on Friday, May 9, 2025, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease, will host a conference call to discuss the results as follows: DateFriday, May 9, 2025 ...

President Donald Trump’s recently imposed tariff has rattled the equity market. The action will weigh on the already slowing domestic economy as the tariff will increase prices of both domestic and imported goods, thereby fueling uncertainty. In this context, creating a curated portfolio of low-beta stocks is a prudent strategy. This provides a safeguard against the uncertain market, equipping investors to navigate volatility with greater resilience and foresight.Hence, stocks like ANI Pharmaceuticals, Inc. ...

Investors in ANI Pharmaceuticals, Inc. (ANIP) need to pay close attention to the stock based on moves in the options market lately. That is because the Apr 17, 2025 $75.00 Put had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It co ...

Despite the challenges, opportunities remain for investors. In a turbulent market like this, stocks demonstrating relative price strength—those that resist broader downturns—can provide stability. This approach highlights resilient companies with strong fundamentals, offering the potential for outperformance as market conditions improve. At this stage, investors would be wise to consider stocks like IHS Holding Limited (IHS) , ANI Pharmaceuticals, Inc. (ANIP) , Pediatrix Medical Group (MD) , Fresenius Medic ...

The S&P 500 index declined more than 5% in the first three months of 2025 amid growing concerns over tariffs, economic uncertainty and the rise of low-cost AI offerings in China. The market is now facing heightened volatility. Yesterday, Goldman Sachs lowered its year-end S&P 500 target due to higher recession risks and expectations of weakening corporate profits. In such an uncertain environment, value investing could prove to be a prudent strategy. Focusing on undervalued stocks with strong fundamentals p ...